Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Sequential radioimmunotherapy with 177Lu- and 211At-labeled monoclonal antibody BR96 in a syngeneic rat colon carcinoma model

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Shelf-life of ɛ-lysyl-3-(trimethylstannyl)benzamide immunoconjugates, precursors for 211At labeling of antibodies

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Comparison of (211)At-PRIT and (211)At-RIT of Ovarian Microtumors in a Nude Mouse Model

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Evaluation of effects on the peritoneum after intraperitoneal α-radioimmunotherapy with (211)At

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Intraperitoneal alpha-radioimmunotherapy in mice using different specific activities

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Various functions of PBMC from colon cancer patients are not decreased compared to healthy blood donors.

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskning

  1. Synthesis and Evaluation of Astatinated N-[2-(Maleimido)ethyl]-3-(trimethylstannyl)benzamide Immunoconjugates

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Absorbed Doses and Risk Estimates of (211)At-MX35 F(ab')2 in Intraperitoneal Therapy of Ovarian Cancer Patients

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. N-[2-(maleimido)ethyl]-3-(trimethylstannyl)benzamide, a molecule for radiohalogenation of proteins and peptides

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Sophie E Eriksson
  • Erika Elgström
  • Tom Bäck
  • Tomas Ohlsson
  • Holger Jensen
  • Rune Nilsson
  • Sture Lindegren
  • Jan Tennvall
Vis graf over relationer

UNLABELLED: Alpha-particle emitters, such as astatine-211 (211At), are generally considered suitable for the treatment of small cell clusters due to their short path length, while beta-particle emitters, for example, Lutetium-177 (177Lu), have a longer path length and are considered better for small, established tumors. A combination of such radionuclides may be successful in regimens of radioimmunotherapy. In this study, rats were treated by sequential administration of first a 177Lu-labeled antibody, followed by a 211At-labeled antibody 25 days later.

METHODS: Rats bearing solid colon carcinoma tumors were treated with 400 MBq/kg body weight 177Lu-BR96. After 25 days, three groups of animals were given either 5 or 10 MBq/kg body weight of 211At-BR96 simultaneously with or without a blocking agent reducing halogen uptake in normal tissues. Control animals were not given any 211At-BR96. Myelotoxicity, body weight, tumor size, and development of metastases were monitored for 120 days.

RESULTS: Tumors were undetectable in 90% of the animals on day 25, independent of treatment. Additional treatment with 211At-labeled antibodies did not reduce the proportion of animals developing metastases. The rats suffered from reversible myelotoxicity after treatment.

CONCLUSIONS: Sequential administration of 177Lu-BR96 and 211At-BR96 resulted in tolerable toxicity providing halogen blocking but did not enhance the therapeutic effect.

OriginalsprogEngelsk
TidsskriftCancer Biotherapy & Radiopharmaceuticals
Vol/bind29
Udgave nummer6
Sider (fra-til)238-46
Antal sider9
ISSN1084-9785
DOI
StatusUdgivet - aug. 2014

ID: 45005718